These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 37581759)

  • 1. Does baricitinib reduce disease activity in patients with systemic lupus erythematosus? A systematic review and meta-analysis of randomized controlled trials.
    Amer BE; Afifi E; Mouffokes A; Hamad AA; Amin AM; Abdelwahab OA
    Clin Rheumatol; 2024 Feb; 43(2):579-589. PubMed ID: 37581759
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of baricitinib for the treatment of systemic lupus erythematosus patients: A meta-analysis of randomized controlled trials.
    Panda AK; Ranjan S; Sahu JK
    Int J Rheum Dis; 2024 Jan; 27(1):e14964. PubMed ID: 37950554
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Baricitinib decreases anti-dsDNA in patients with systemic lupus erythematosus: results from a phase II double-blind, randomized, placebo-controlled trial.
    Dörner T; van Vollenhoven RF; Doria A; Jia B; Ross Terres JA; Silk ME; de Bono S; Fischer P; Wallace DJ
    Arthritis Res Ther; 2022 May; 24(1):112. PubMed ID: 35578304
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-II).
    Petri M; Bruce IN; Dörner T; Tanaka Y; Morand EF; Kalunian KC; Cardiel MH; Silk ME; Dickson CL; Meszaros G; Zhang L; Jia B; Zhao Y; McVeigh CJ; Mosca M
    Lancet; 2023 Mar; 401(10381):1011-1019. PubMed ID: 36848919
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Wallace DJ; Furie RA; Tanaka Y; Kalunian KC; Mosca M; Petri MA; Dörner T; Cardiel MH; Bruce IN; Gomez E; Carmack T; DeLozier AM; Janes JM; Linnik MD; de Bono S; Silk ME; Hoffman RW
    Lancet; 2018 Jul; 392(10143):222-231. PubMed ID: 30043749
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety study of targeted small-molecule drugs in the treatment of systemic lupus erythematosus.
    Wang S; Ning W; Tang H; Mu C; Huang X
    Arthritis Res Ther; 2024 May; 26(1):98. PubMed ID: 38730460
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and Safety of Tofacitinib, Baricitinib, and Upadacitinib for Rheumatoid Arthritis: A Systematic Review and Meta-Analysis.
    Wang F; Sun L; Wang S; Davis JM; Matteson EL; Murad MH; Luo F; Vassallo R
    Mayo Clin Proc; 2020 Jul; 95(7):1404-1419. PubMed ID: 32499126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Baricitinib Attenuates Autoimmune Phenotype and Podocyte Injury in a Murine Model of Systemic Lupus Erythematosus.
    Lee J; Park Y; Jang SG; Hong SM; Song YS; Kim MJ; Baek S; Park SH; Kwok SK
    Front Immunol; 2021; 12():704526. PubMed ID: 34497607
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Extended Safety Analysis of Baricitinib 2 mg in Adult Patients with Atopic Dermatitis: An Integrated Analysis from Eight Randomized Clinical Trials.
    King B; Maari C; Lain E; Silverberg JI; Issa M; Holzwarth K; Brinker D; Cardillo T; Nunes FP; Simpson EL
    Am J Clin Dermatol; 2021 May; 22(3):395-405. PubMed ID: 33826132
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Efficacy and safety of Janus kinase inhibitors in systemic and cutaneous lupus erythematosus: A systematic review and meta-analysis.
    Ma L; Peng L; Zhao J; Bai W; Jiang N; Zhang S; Wu C; Wang L; Xu D; Leng X; Wang Q; Zhang W; Zhao Y; Tian X; Li M; Zeng X
    Autoimmun Rev; 2023 Dec; 22(12):103440. PubMed ID: 37678618
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval.
    Loncharich MF; Anderson CW
    ACR Open Rheumatol; 2022 Jun; 4(6):486-491. PubMed ID: 35157371
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Baricitinib in the treatment of systemic lupus erythematosus: a systematic review of randomized controlled trials.
    Shah HH; Ashfaque F; Hadi Z; Waseem R; Rauf SA; Hussain T; Anas Z; Zehra SA; Hussain MS; Wasay Zuberi MA; Haque MA
    Ann Med Surg (Lond); 2024 Aug; 86(8):4738-4744. PubMed ID: 39118746
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Baricitinib for systemic lupus erythematosus: a double-blind, randomised, placebo-controlled, phase 3 trial (SLE-BRAVE-I).
    Morand EF; Vital EM; Petri M; van Vollenhoven R; Wallace DJ; Mosca M; Furie RA; Silk ME; Dickson CL; Meszaros G; Jia B; Crowe B; de la Torre I; Dörner T
    Lancet; 2023 Mar; 401(10381):1001-1010. PubMed ID: 36848918
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of baricitinib in treatment of systemic lupus erythematosus: a systematic review and meta-analysis.
    Allam AR; Alhateem MS; Mahmoud AM
    BMC Rheumatol; 2023 Oct; 7(1):40. PubMed ID: 37904221
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Baricitinib-associated changes in global gene expression during a 24-week phase II clinical systemic lupus erythematosus trial implicates a mechanism of action through multiple immune-related pathways.
    Dörner T; Tanaka Y; Petri MA; Smolen JS; Wallace DJ; Dow ER; Higgs RE; Rocha G; Crowe B; Benschop RJ; Byers NL; Silk ME; de Bono S; Fantini D; Hoffman RW
    Lupus Sci Med; 2020 Oct; 7(1):. PubMed ID: 33037080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Janus kinase inhibitors in atopic dermatitis: an umbrella review of meta-analyses.
    He Q; Xie X; Chen Q; Li W; Song Z; Wang X; Ma X; Zeng J; Guo J
    Front Immunol; 2024; 15():1342810. PubMed ID: 38464512
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Long-term efficacy and safety of baricitinib in patients with severe alopecia areata: 104-week results from BRAVE-AA1 and BRAVE-AA2.
    Senna M; Mostaghimi A; Ohyama M; Sinclair R; Dutronc Y; Wu WS; Yu G; Chiasserini C; Somani N; Holzwarth K; King B
    J Eur Acad Dermatol Venereol; 2024 Mar; 38(3):583-593. PubMed ID: 38391212
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A Review of Safety Outcomes from Clinical Trials of Baricitinib in Rheumatology, Dermatology and COVID-19.
    Bieber T; Feist E; Irvine AD; Harigai M; Haladyj E; Ball S; Deberdt W; Issa M; Grond S; Taylor PC
    Adv Ther; 2022 Nov; 39(11):4910-4960. PubMed ID: 36063279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical efficacy and safety of Janus kinase inhibitors for COVID-19: A systematic review and meta-analysis of randomized controlled trials.
    Chen CY; Chen WC; Hsu CK; Chao CM; Lai CC
    Int Immunopharmacol; 2021 Oct; 99():108027. PubMed ID: 34343937
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and safety of baricitinib for the treatment of moderate-to-severe atopic dermatitis: A systematic review and meta-analysis of randomized clinical trials.
    Wang B; Pan S; Yao Y; Zeng L; Zhang G
    Clin Exp Pharmacol Physiol; 2022 Nov; 49(11):1139-1149. PubMed ID: 35876397
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.